Scott Scott Franklin

RepublicanFL18•house•Filed Apr 11, 2025

View all of Scott Scott Franklin's trades →41 total filings on record

Scott Scott Franklin (R-FL) bought $15K-$50K of $NVO (Novo Nordisk A/S Common Stock (NVO)) on Mar 27, 2025, part of 2 transactions in this filing.

HillSignal flagged 1 timing concern on this filing — trades that line up closely with related legislative or contract activity.

Transactions

Companies

Largest Trade

$15K-$50K

Timing Flags

Companies in this filing

$NVO-41.3%

Price Movement Since Trade

How the largest positions have moved from the trade date to the most recent close.

$NVO✗ LOSING

Health Care

Trade Day

$70.16

Mar 27, 2025

Current

$41.17

Apr 24, 2026

Change

-41.32%

$-28.99

Full chart on TradingView →

🔒

Sign Up to See More

See the full trade breakdown, suspicious timing flags, and how this filing connects to active legislation.

Get Free Access →

Suspicious Timing Detected

1 flag

Rep. Scott Scott Franklin bought $15,001-$50,000 and $1,001-$15,000 in $NVO on March 27, 2025 — 70 days before the "Treat and Reduce Obesity Act of 2025" (S1973) was introduced, a bill that could affect companies like Novo Nordisk.

These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.

Share This Filing

Share on X Reddit Facebook

All Transactions

Type	Ticker	Asset	Amount	Trade Price	Current	Change	Date
BUY	$NVO	Novo Nordisk A/S Common Stock (NVO)	$15K-$50K	$70.16	$41.17	-41.3%	Mar 27, 2025
BUY	$NVO	Novo Nordisk A/S Common Stock (NVO)	$1K-$15K	$70.16	$41.17	-41.3%	Mar 27, 2025

BUY$15K-$50K

$NVONovo Nordisk A/S Common Stock (NVO)

$70.16 \u2192 $41.17-41.3%

Mar 27, 2025 \u2022 self

BUY$1K-$15K

$NVONovo Nordisk A/S Common Stock (NVO)

$70.16 \u2192 $41.17-41.3%

Mar 27, 2025 \u2022 self

Connected Legislative Activity

1 signal

These bills and contracts share tickers or sectors with this filing's trades.

BillS1973bullish

Treat and Reduce Obesity Act of 2025

The Treat and Reduce Obesity Act of 2025 would mandate Medicare Part D coverage of GLP-1 obesity drugs, unlocking a massive new payer market of ~27 million beneficiaries. $NVO and $LLY are the two direct beneficiaries. The bill is in early-stage committee referral with 22 bipartisan cosponsors; no companion bill has passed the House yet. Real market data shows $NVO gaining 15.56% over 30 days vs $LLY's +0.7%, suggesting the market may be overweighting Novo's near-term Medicare exposure given its larger U.S. obesity market share.

Jun 5, 2025

LLYNVO

Other Filings by Scott Scott Franklin

Oct 22, 20256 trades⚠ Flagged

$IVV$UNP

Aug 15, 20254 trades

$NVO$CMCSA

View Original PDF \u2190 Browse All Filings

Free — no credit card

Get the next Franklin trade the day it's disclosed

HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →

Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.